1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Acute Myeloid Leukemia (AML) Therapeutics Market
2.3. Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Drugs, 2025 (US$ Million)
2.4. Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Geography, 2025 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2025
3. Acute Myeloid Leukemia (AML) Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Acute Myeloid Leukemia (AML) Therapeutics Market Vendors
3.2. Strategies Adopted by Acute Myeloid Leukemia (AML) Therapeutics Market Vendors
4. Acute Myeloid Leukemia (AML) Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Acute Myeloid Leukemia (AML) Therapeutics Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape
5. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Cell Culture Vaccines
5.3.1.1. Cytarabine
5.3.1.2. Anthracyclines
5.3.1.3. Etoposide
5.3.1.4. Others
5.3.2. Pipeline Drugs
6. North America Acute Myeloid Leukemia (AML) Therapeutics Market, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
6.3. Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2024-2034, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
7. UK and European Union Acute Myeloid Leukemia (AML) Therapeutics Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
7.3. Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2024-2034, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
7.3.1.5. France
7.3.1.5.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
8. Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
8.3. Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2024-2034, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
8.3.1.3. India
8.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
9. Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
9.3. Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2024-2034, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
10. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
10.3. Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2024-2034, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2024-2034, USD (Million)
11. Company Profile
11.1. Abbott Laboratories (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical)
11.3. Boehringer Ingelheim GmbH
11.4. Bristol Myers Squibb
11.5. Celegene Corporation
11.6. Cephalon Inc.
11.7. Eisai Co. Ltd.
11.8. Eli Lilly and Company
11.9. Genzyme Corporation (A subsidiary of Sanofi S.A.)
11.10. Jazz Pharmaceuticals, Inc.
11.11. Novartis AG
11.12. Pfizer Inc.
